| 69.535 -4.465 (-6.03%) | 05-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 88.18  |
1-year : | 102.99 |
| Resists | First : | 75.5 |
Second : | 88.18 |
| Pivot price | 68.36 |
|||
| Supports | First : | 67.79 |
Second : | 63.02 |
| MAs | MA(5) : | 70.9 |
MA(20) : | 69.04 |
| MA(100) : | 59.03 |
MA(250) : | 43.49 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 78.4 |
D(3) : | 76.9 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 75.5 | Low : | 23.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CGON ] has closed below upper band by 37.5%. Bollinger Bands are 6.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 75.59 - 75.99 | 75.99 - 76.33 |
| Low: | 67.2 - 67.62 | 67.62 - 67.97 |
| Close: | 68.84 - 69.56 | 69.56 - 70.17 |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Fri, 08 May 2026
CG Oncology (NASDAQ: CGON) boosts cash above $1.0B as R&D loss grows - Stock Titan
Fri, 08 May 2026
CG Oncology (NASDAQ: CGON) posts Q1 2026 loss but builds $1.1B cash runway - Stock Titan
Tue, 21 Apr 2026
CGON SEC Filings - CG Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 20 Apr 2026
Cg oncology director James Mulay reduces stake by $1.14m - Investing.com
Mon, 20 Apr 2026
CG Oncology (CGON) director exits 15,600-share position via 10b5-1 sale - Stock Titan
Thu, 16 Apr 2026
Officer at CG Oncology (CGON) awarded 45,266 stock options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 6.904e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 10,550 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8933e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 97.3 % |
| Return on Equity (ttm) | -15.5 % |
| Qtrly Rev. Growth | 4.04e+006 % |
| Gross Profit (p.s.) | 584.57 |
| Sales Per Share | -30.96 |
| EBITDA (p.s.) | -1.675e+008 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.25 |
| Price to Cash Flow | 5.21 |
| Dividend | 0 |
| Forward Dividend | 9.53e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|